Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

PROMISE

Financiado

Portal Range Monitoring in Mixed Ion Beam Surgery

Half of the approximately 4 million annual cancer cases in Europe receive radiotherapy. While many cancer patients have benefitted from technical improvements in recent years, widespread diseases, such as pancreatic and lung cance... ver más

28/02/2029

GSI

2M€

Presupuesto del proyecto: 2M€

Líder del proyecto

GSI HELMHOLTZZENTRUM FUR SCHWERIONENFORSCHUNG... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2024-02-23

ERC-2023-COG: ERC CONSOLIDATOR GRANTS Scope:Objectives

I+D

Cerrada hace 1 año

0% 100% 100%

1 Participantes

GSI

2.00M€ | Lider

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

SAF2008-03692 RADIOTERAPIA CON HACES DE ELECTRONES MODULADOS EN COMBINACIO... 139K€ Cerrado

FIS2010-17007 DOSIMETRIA EN BRAQUITERAPIA Y APLICACIONES CLINICAS 73K€ Cerrado

PDC2022-133382-I00 PROTON RANGE AND IMAGING DEVICE FOR PROTONTHERAPY 150K€ Cerrado

PDC2022-133605-I00 TELESCOPIO PARA CT DE PROTONES HA HADRONTERAPIA 115K€ Cerrado

SAF2011-27116 DESARROLLO TEORICO Y EVALUACION CLINICA DE LA TECNICA RADIOT... 145K€ Cerrado

Duración del proyecto: 60 meses Fecha Inicio: 2024-02-23
Fecha Fin: 2029-02-28

Líder del proyecto

GSI HELMHOLTZZENTRUM FUR SCHWERIONENFORSCHUNG... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 2M€

Descripción del proyecto Half of the approximately 4 million annual cancer cases in Europe receive radiotherapy. While many cancer patients have benefitted from technical improvements in recent years, widespread diseases, such as pancreatic and lung cancer, still have dismally low cure rates, with median survival of less than 2 years. Carbon ion radiotherapy (CIRT) offers unprecedented precision in delivering tumour dose, and can be the much needed game changer for these patients. However, CIRT is vulnerable to uncertainties in patient positioning, anatomy changes and organ motion. The current clinical approach is to increase the high dose volume to ensure target coverage, counteracting the primary advantage of CIRT. Novel strategies for image guidance and beam range assessment are crucial to unlock the full potential of CIRT for the best possible patient care. PROMISE, for the first time, will produce mixed ion beams that enable concurrent treatment and image guidance. Carbon ions deliver the dose to the target while Helium ions, simultaneously accelerated to the same velocity, traverse the patient and monitor tumour location and beam range. PROMISE realizes true portal imaging, providing real-time information on the target anatomy as seen by the treatment beam. Coupled with innovative detectors, AI-based image recognition, and online dose reconstruction, this technique will enable to drastically reduce safety margins, and achieve the full potential of CIRT. The GSI accelerators are uniquely suited to develop the first mixed beam of Carbon and Helium, along with strategies for their cost-effective translation to existing and future clinical CIRT centres. The method will be validated experimentally in GSI’s former CIRT treatment room. Patient simulation studies will highlight clinical benefit and characterize ideal use cases. A demonstration in an animal model will pave the way for clinical transition. The mixed beam image guidance of PROMISE will lead to a paradigm shift in CIRT.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores